The EU recently approved glecaprevir/pibrentasvir (Maviret), an eight-week direct-acting antiviral regimen, which offers people with hepatitis C the fastest treatment option available, giving European...

The regulatory body approved AbbVie's glecaprevir/pibrentasvir (Maviret) for the treatment of acute hepatitis C virus infection in adults and children aged 3 years and older, making it the first and o...

The regulatory body approved AbbVie's glecaprevir/pibrentasvir (Maviret) for the treatment of acute hepatitis C virus infection in adults and children aged 3 years and older, making it the first and o...

The European Commission has approved glecaprevir/pibrentasvir (Maviret) for acute hepatitis C virus (HCV) infection, making it the only therapy approved in the European Union for both acute and chroni...

Find out where to fill your Maviret prescription.

Maviret New Zealand. If you’ve been living with hep C for years, you could now be cured, with just 8 weeks treatment*

The European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral therapy for the treatment of acute hepatitis C virus infection in adults and children aged 3 years and older. With this approval, Maviret is now the only treatment approved in the European Union for both acute and chronic HCV infection. To access this subscriber-only […]

European regulators have recommended expanding Maviret, a dual direct-acting antiviral, to include acute hepatitis C infection in adults and children.

AbbVie announced that its drug MAVIRET received a positive opinion from Europe's medicines committee for treating acute hepatitis C infections in both adults and children aged three years or older. If...

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to...

Reported Tuesday, Jun 23 - 5:58am EDT (TheFly subscription required to read more.)

Reported Tuesday, Jun 23 - 5:56am EDT (TheFly subscription required to read more.)

Reported Friday, May 22 - 8:01am EDT (TheFly subscription required to read more.)

AbbVie has announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus infection in adults and children aged three years and older. The approval also expands the medicine’s use across the European Union for both acute and chronic hepatitis C, strengthening AbbVie’s antiviral portfolio. The decision follows a [...]

AbbVie's MAVIRET® is now authorized in the EU for acute hepatitis C treatment, enhancing timely intervention for millions at risk.

AbbVie has received a positive opinion from the CHMP for MAVIRET® to treat acute hepatitis C infections, benefiting both adults and children. This treatment aims to enhance early intervention and HCV elimination.

AbbVie (NYSE: ABBV) announced a positive CHMP opinion recommending approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C in adults and children ≥3 years in the EU. The opinion is based on Phase 3 M20-350 data showing a 96% cure rate (SVR12) over eight weeks, with a safety profile generally consistent with prior experience. A final European Commission decision is expected in Q3 2026, which would expand MAVIRET’s indication to both acute and chronic HCV.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.